Stull, Stull & Brody Announces Investigation on Behalf of Participants and Beneficiaries of the GlaxoSmithKline Retirement

NEW YORK--(BUSINESS WIRE)-- Attorney Advertising. Stull, Stull & Brody announced today that it has commenced an investigation relating to the 401(k) defined contribution retirement plan of GlaxoSmithKline plc (NYSE:GSK). Among other things, Stull, Stull & Brody is investigating whether fiduciaries of the GlaxoSmithKline 401(k) plan may have violated the Employee Retirement Income Security Act of 1974 (“ERISA”) by failing to disclose the Company’s true operating condition to participants and beneficiaries of the plans (including disclosures relating disclosures relating to the safety of Avandia, a diabetes drug), by offering GlaxoSmithKline ADRs as an investment option under the plans when it was not prudent to do so, and/or by allowing an imprudent overconcentration of Company stock in the Company’s 401(k) plans.

If you held GlaxoSmithKline stock in an individual account under any the Company’s 401(k) plan or employee stock ownership plan you may, if you wish, consult with a representative of Stull, Stull & Brody at no cost or obligation. The contact information for Stull, Stull & Brody is as follows:

Email: [email protected]

Fax: (212) 490-2022
Toll Free Number: 1-800-337-4983
(Michael J. Klein, Esq.)
 
Mail: Stull, Stull & Brody
6 East 45th Street
New York, NY 10017

Stull, Stull & Brody has extensive experience in protecting the rights of 401(k) plan participants and beneficiaries and shareholders of public companies. Stull, Stull & Brody is presently representing classes of 401(k) plan participants in many class action cases throughout the country. Stull, Stull & Brody maintains offices in New York and Los Angeles.

Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.



CONTACT:

Stull, Stull & Brody
Michael J. Klein, Esq., 1-800-337-4983
Fax: 212-490-2022
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  New York

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Professional Services  Legal

MEDIA:

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.